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Background:  Bone marrow (BM)-derived human mesenchymal stem cells (hMSCs) may ameliorate consequences of myocardial infarction, and 
have the advantages of capacity to home to injured tissue, and extensive pre-clinical support. Our aim was to investigate the safety and efficacy of 
intracoronary autologus hMSCs in patients with acute myocardial infarction (AMI).
Methods:  The hMSCs (Phamicell, Inc., SeungNam, Korea) were manufactured in a manner consistent with International Conference on 
Harmonization and Food and Drug Administration regulatory guidelines. This clinical study was approved from Korean FDA and we performed a 
randomized, open labeled, multicenter trial to evaluate the safety and efficacy of intracoronary autologus BM-derived hMSC administration (5-10 x 
107 hMSCs) for patients with successful primary percutaneous coronary intervention (PCI) after AMI .
The primary end points were incidence of treatment-emergent adverse events within 6 months and comparison of left ventricular ejection fraction 
(LVEF) by single-photon emission computed tomography (SPECT).
Results:  A total of 59 patients enrolled at 4 participating study centers completed the trial through the 6-month time point, with safety and 
exploratory efficacy end points evaluated at 1, and 6-month follow-up visits. There is no significant difference for demographic and clinical factors 
between group with hMSC therapy (n=30, 52.6 years , 77% male) and group without hMSC therapy (n=29, 54.2 years , 86% male). There was no 
evidence of increased toxicity with the administration of hMSCs and administration was well tolerated at given cell dose levels. Baseline LVEF by 
SPECT was similar between patient groups (49.0±11.7% in hMSC treated patients, and 52.2±9.1% in only PCI patients, p=0.251). Overall, patients 
treated with hMSCs experienced a 5.9 ± 8.5% increase in LVEF at 6 months compared with a 1.7±6.9% increase in the only PCI group (p=0.043). 
There is no difference for cardiovascular events.
Conclusions:  Intracoronary autologous BM-derived hMSCs are safe in patients after AMI. This trial provides pivotal safety and provisional efficacy 
data for an autologous bone marrow-derived stem cell in post-infarction patients.
